source
- Drugmakers Rethink Launch Strategies as MFN Pricing Rules Shake MarketA new Numerof & Associates report says that the rollout of Most Favored Nation (MFN) pricing rules is forcing drugmakers to overhaul how they choose launch markets. Executives surveyed said the Un…
- FDA proposes 50% fee cut for US early-stage trials, but industry says speed matters moreThe FDA announced a proposal to cut the application fee by half for drugs that run their early-stage trials in the United States. The reduction, about $2.3 million at current rates, is intended to…